- Home
- INMB vs RAND Comparison
INMB vs RAND Comparison
Compare INMB & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INMB | RAND |
|---|---|---|
| Founded | 2015 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.4M | 34.6M |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | INMB | RAND |
|---|---|---|
| Price | $1.59 | $10.92 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.40 | N/A |
| AVG Volume (30 Days) | ★ 364.9K | 1.7K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 10.83% |
| EPS Growth | ★ 11.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 257.14 | N/A |
| 52 Week Low | $1.09 | $10.05 |
| 52 Week High | $11.64 | $20.00 |
Technical Indicators
Market Signals| Indicator | INMB | RAND |
|---|---|---|
| Relative Strength Index (RSI) | 57.51 | 49.33 |
| Support Level | $1.38 | $10.58 |
| Resistance Level | $1.71 | $11.15 |
| Average True Range (ATR) | 0.11 | 0.26 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 54.17 | 35.96 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.